Why the study?
Does intravenous dobutamine improve haemodynamic parameters in patients with chronic congestive cardiac failure?
Does intravenous dobutamine improve haemodynamic parameters in patients with chronic congestive cardiac failure?
Intravenous dobutamine significantly improves cardiac output and stroke volume with only moderate increases in heart rate in patients with chronic congestive cardiac failure.
Supports acute hemodynamic assessment of dobutamine in chronic heart failure; hypothesis-generating and requires prospective validation before clinical adoption.
The haemodynamic effects of dobutamine were studied in 14 patients with chronic congestive cardiac failure. Heart rate, central venous, pulmonary arterial, pulmonary wedge, and aortic pressures, aortic dp/dt, cardiac output, cardiac index, stroke volume, and pulmonary and systemic vascular resistances were measured or derived. Dose-response curves were obtained by recording all measurements before and after intravenous infusion of dobutamine at rates of 2.5, 5, and 10 mug/kg per min for periods of 30 minutes each. Significant increases in mean values were observed for cardiac output from 3.7 to 6.4 l/min (82%), for stroke volume from 44 to 64 ml (39%), and aortic dp/dt from 692 to 1414 mmHg/s (92.0 to 188.1 kPa/s (76%). Heart rate increased only moderately from 86 to 101 per minute (31%). Significant reduction occurred in pulmonary wedge and central venous pressures. Mean aortic and pulmonary pressures did not change significantly, as a measure of decreased vascular resistances. The drug was uniformly well tolerated. The predominant inotropic effects of dobutamine without tachycardia or arrhythmias may be valuable in severe heart failure.
No takes yet. Share an insight, caveat, or question.
Beregovich et al. (1975) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: